Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Curr Eye Res ; 37(7): 592-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22559281

ABSTRACT

PURPOSE: To compare the optic nerve head (ONH) and retinal nerve fiber layer (RNFL) in eyes with narrow angles and normal intraocular pressure (IOP) to normal control eyes. MATERIALS AND METHODS: A total of 70 eyes of 52 subjects with narrow angles and 40 eyes of 34 normal subjects were enrolled. Narrow angle eyes were defined as the following: (i) the pigmented trabecular meshwork was not visible for ≥ 180° on gonioscopy, (ii) untreated IOP ≤ 21 mmHg, (iii) no peripheral anterior synechiae (PAS) was observed, and (iv) optic discs were without glaucomatous changes, defined as neuroretinal rim thinning, focal notching, disc hemorrhages, or focal RNFL defects. ONH and peripapillary RNFL imaging were obtained with Heidelberg Retina Tomograph (HRT II) and Fourier-domain optical coherence tomography (RTVue OCT). RESULTS: No significant difference was found in mean age between the two groups (p = 0.06), but the narrow angle group had significantly more women (p = 0.04). The narrow angle group had significantly higher IOP and smaller mean angle width (both p < 0.001). Vertical cup-to-disc ratio (VCDR) was significantly larger in the narrow angle group (p = 0.02). In visual field (VF) results, the mean deviation (MD) was significantly lower and pattern standard deviation (PSD) was significantly higher in the narrow angle group (both p < 0.001). After adjusting for disc area, the RNFL thickness of the inferior-temporal region was significantly thinner in the narrow angle group (135 ± 21.7 µm) compared with normal group (149 ± 22.1 µm, p < 0.01). This finding remained significant after Bonferroni correction for multiple comparisons. Smaller angle width was a significant predictor of RNFL thinning in the inferior-temporal region (p < 0.001). CONCLUSION: These data suggest that eyes with narrow angles may develop glaucomatous optic nerve damage in the absence of IOP elevation during office hours.


Subject(s)
Glaucoma, Angle-Closure/diagnosis , Glaucoma, Open-Angle/diagnosis , Nerve Fibers/pathology , Optic Disk/pathology , Optic Nerve Diseases/diagnosis , Retinal Ganglion Cells/pathology , Adult , Aged , Aged, 80 and over , Female , Fourier Analysis , Glaucoma, Angle-Closure/surgery , Glaucoma, Open-Angle/surgery , Gonioscopy , Humans , Intraocular Pressure , Iris/surgery , Laser Therapy , Lasers, Solid-State , Male , Middle Aged , Pilot Projects , Prospective Studies , Tomography, Optical Coherence , Visual Field Tests
2.
J Formos Med Assoc ; 103(5): 369-73, 2004 May.
Article in English | MEDLINE | ID: mdl-15216404

ABSTRACT

BACKGROUND AND PURPOSE: Brinzolamide is a new topical carbonic anhydrase inhibitor for intraocular pressure (IOP) control. It has high inhibitory activity against human carbonic anhydrase II, which is the key isoenzyme regulating aqueous humor production. We conducted this study to compare the ocular hypotensive effect and safety of 1% brinzolamide versus that of 0.5% timolol twice daily. METHODS: In a double-masked design, 50 open angle glaucoma patients who had a baseline IOP between 20 to 30 mm Hg were randomized to receive either 1% brinzolamide ophthalmic solution or 0.5% timolol twice daily. After completing a 2-week pre-study screening period, patients were scheduled to receive 6 weeks of treatment. Visual acuity, IOP, slit-lamp biomicroscopy, corneal thickness, refraction status, blood pressure, heart rate, and treatment-related signs and symptoms were evaluated at follow-up visits. The eye selected for treatment was the one with the higher baseline IOP, or the right eye if the IOPs were the same in both eyes. The fellow eye served as control. RESULTS: 48 patients completed the study, and there were 24 patients in each group. A significant decrease in mean IOP was found after 6 weeks of treatment in both the brinzolamide group (-17.0%) and the timolol group (-19.7%), with no significant between-group difference in the control of IOP. The central corneal thickness of treatment eyes, measured by ultrasound pachometry, had not changed after 6 weeks of brinzolamide treatment. The study medications were generally well tolerated and no serious adverse reactions occurred during the 6-week study period. CONCLUSION: When used twice a day, topical brinzolamide is as effective as 0.5% timolol in lowering IOP in patients with open angle glaucoma.


Subject(s)
Carbonic Anhydrase Inhibitors/therapeutic use , Glaucoma, Open-Angle/drug therapy , Sulfonamides/therapeutic use , Thiazines/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists/pharmacology , Adrenergic beta-Antagonists/therapeutic use , Adult , Carbonic Anhydrase Inhibitors/adverse effects , Carbonic Anhydrase Inhibitors/pharmacology , Consumer Product Safety , Double-Blind Method , Female , Humans , Intraocular Pressure/drug effects , Male , Ophthalmic Solutions , Sulfonamides/adverse effects , Sulfonamides/pharmacology , Thiazines/adverse effects , Thiazines/pharmacology , Timolol/adverse effects , Timolol/pharmacology , Timolol/therapeutic use
3.
J Ocul Pharmacol Ther ; 19(5): 417-23, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14583134

ABSTRACT

This was a 6-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination b.i.d. to the concomitant administration of 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d. Patients with ocular hypertension or open-angle glaucoma from 21 to 85 years of age were enrolled in this study. Each of them should have intraocular pressure (IOP) of 20 mmHg or more in the study eye after they completed the wash-out period. The patients enrolled were randomly assigned to either combination (0.5% timolol/2.0% MK-507 b.i.d. and placebo b.i.d.) or concomitant (0.5% timolol b.i.d. and 2.0% MK-507 b.i.d.) treatment. During the study, no systemic or topical medication affecting IOP other than test drugs were allowed. A total of 20 randomized patients were included in the intention-to-treat population for analysis of data. The ten were assigned to the combination treatment and others were assigned to the concomitant treatment. There was no statistically significant difference between the two study treatments in terms of gender distribution, average age, and average IOP at the trough and the peak before starting the test medications. Mean reduction of the IOP from baseline to the final visit at the trough was 5.04 mmHg in the combination treatment and was 2.73 mmHg in the concomitant treatment. Mean reduction of the IOP at the peak was 2.19 mmHg in the combination treatment and was 2.53 mmHg in the concomitant treatment. There were no statistically significant differences in the above analyses between the two treatments. Safety evaluation was carried out, and number of adverse events in each treatment group did not differ substantially. Ocular signs and symptoms were evaluated in each visit, and all of the between-treatment values were not different significantly, either. Laboratory tests were performed, and showed no significant differences between pre- and post-treatment periods. None of these was found to be clinically serious, either. We concluded that the 0.5% timolol/2.0% MK-507 combination b.i.d. is equivalent in the efficacy of lowering IOP as well as safety compared to the concomitant administration of 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d. in patients with ocular hypertension or open-angle glaucoma.


Subject(s)
Intraocular Pressure/drug effects , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Thiophenes/administration & dosage , Thiophenes/adverse effects , Timolol/administration & dosage , Timolol/adverse effects , Adult , Double-Blind Method , Drug Therapy, Combination , Female , Glaucoma, Open-Angle/drug therapy , Glaucoma, Open-Angle/physiopathology , Humans , Intraocular Pressure/physiology , Male , Middle Aged , Ocular Hypertension/drug therapy , Ocular Hypertension/physiopathology , Statistics, Nonparametric
4.
Surv Ophthalmol ; 47 Suppl 1: S125-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12204708

ABSTRACT

Two independent, prospective trials were recently conducted to assess the efficacy of latanoprost in reducing intraocular pressure (IOP) in patients with primary angle-closure glaucoma (PACG). The first study was a 2-week, randomized, double-masked comparison of latanoprost treatment and timolol treatment in patients with PACG. Patients were randomized to one of two parallel treatment groups, receiving either placebo in the morning and latanoprost 0.005% in the evening, or timolol 0.5% twice daily. The mean IOP reduction in latanoprost group was 8.8 +/- 1.1 mm Hg (mean +/- SEM, p < 0.001; 34.2%) from a mean baseline IOP of 25.7 +/- 0.9 mm Hg, and the corresponding figures for the timolol group were 5.7 +/- 0.9 mm Hg (p < 0.001; 22.6%) from a mean baseline IOP of 25.2 +/- 1.1 mm Hg. A significantly greater IOP reduction of 3.1 +/- 1.5 mm Hg (95% confidence interval: 0.1 to 6.0) was achieved in the latanoprost group compared to the timolol treatment group (p = 0.04). In the second study, latanoprost 0.005% once a day was added adjunctively to PACG patients with persistently elevated IOP after iridectomy, despite treatment with beta-blockers and pilocarpine. The IOP decreased by about 21% during the first 3 months, and showed a reduction of about 36% at the end of 1 year. At the 1-year follow-up, IOP was <20 mm Hg in all eyes. In both studies, latanoprost was well tolerated with few adverse events. These results demonstrate that latanoprost is effective in reducing IOP in patients with PACG.


Subject(s)
Antihypertensive Agents/therapeutic use , Glaucoma, Angle-Closure/drug therapy , Intraocular Pressure/drug effects , Prostaglandins F, Synthetic/therapeutic use , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists/therapeutic use , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/adverse effects , Double-Blind Method , Humans , Latanoprost , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/adverse effects , Ophthalmic Solutions/therapeutic use , Prospective Studies , Prostaglandins F, Synthetic/administration & dosage , Prostaglandins F, Synthetic/adverse effects , Safety , Timolol/administration & dosage , Timolol/adverse effects , Timolol/therapeutic use
5.
J Ocul Pharmacol Ther ; 18(2): 99-103, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12002673

ABSTRACT

The purpose of this study was to evaluate the efficacy of 0.2% brimonidine tartrate in preventing intraocular pressure (IOP) elevation in the dark-prone provocative test for primary angle-closure glaucoma (PACG). Twenty-two eyes from 22 patients with angle-closure glaucoma were enrolled in this study. Each of the selected eyes had previously tested positive in a recent dark-prone test. One drop of 0.2% brimonidine tartrate was then instilled in each eye 2 hours prior to a second dark-prone test. An IOP elevation of greater than 8 mmHg was regarded as a positive result. The IOP elevation in the first dark-prone test was 11.91 +/- 5.17 (range: 5.7 - 27.3) mmHg, while the IOP only increased 5.70 - 2.96 (range: 2.9 - 12.2) mmHg in the second dark-prone test that was pre-treated with 0.2% brimonidine tartrate (p < 0.001). A significant difference was also noted in the pre-test IOP (15.59 +/- 3.86 mmHg vs. 13.33 +/- 3.65 mmHg, p = 0.008) as well as in the post-test IOP (27.62 +/- 7.27 mmHg vs. 19.03 +/- 3.50 mmHg, p < 0.001) in the two sequential dark-prone tests. All but three of the initially positive dark-prone tests (86.46%) converted to negative tests after pre-treatment with brimonidine. There was a significant effect of 0.2% brimonidine tartrate in the prevention of IOP elevation in PACG patients previously found to test positive in the dark-prone provocative test.


Subject(s)
Glaucoma, Angle-Closure/diagnosis , Glaucoma, Angle-Closure/physiopathology , Intraocular Pressure/drug effects , Quinoxalines/therapeutic use , Adult , Aged , Brimonidine Tartrate , Darkness , Female , Humans , Male , Middle Aged , Posture , Prone Position
SELECTION OF CITATIONS
SEARCH DETAIL